Building a Scalable ODF Manufacturing Line: A Guide to Pharmaceutical Film Production

Oral dissolving films (ODFs) have rapidly gained popularity in pharmaceutical and nutraceutical delivery due to their convenience, rapid onset of action, and patient-friendly format. Whether for pediatric, geriatric, or lifestyle medicine, ODFs represent the future of oral drug delivery.

To meet growing demand, pharmaceutical companies are adopting ODF manufacturing lines that can scale from pilot production to full commercial output—while ensuring regulatory compliance, operational efficiency, and consistent film quality.

What is ODF Manufacturing?

ODF (Oral Disintegrating Film) production involves several key steps:

• Emulsification: Blending APIs and excipients into a uniform film-forming solution
• Casting & Coating: Evenly applying the solution onto a substrate
• Drying: Controlled evaporation to form a flexible, stable film
• Cutting & Packaging: Precision cutting into individual doses and integration with packaging

Common Challenges in ODF Production

• Maintaining consistent thickness and drug content uniformity
• Preventing air bubbles, cracks, or delamination
• Balancing drying speed with film integrity
• Ensuring cutting accuracy and clean edges

HUANGHAI's ODF Manufacturing Solution

HUANGHAI offers modular, customizable equipment for every stage of ODF production, from R&D to commercial scale. Key components include:

• Inline or batch emulsification tanks (optional)
• Casting systems with adjustable coating width and thickness
• Multistage drying tunnels with programmable temperature zones
• Precision cutting and slitting units compatible with film-based formats
• Flexible packaging solutions for strips or sachets

Why Choose HUANGHAI

• Custom configurations for various drug loads, film dimensions, and packaging styles
• Facility planning support including CAD layout design
• In-house testing lab to evaluate formulation behavior and machine compatibility
• GMP-compliant construction and full technical documentation
• Installation, training, and global support available

Typical Applications

• Prescription oral thin films (e.g., pain relief, allergy, CNS-targeted drugs)
• Nutraceutical strips (e.g., vitamins, herbal actives)
• Mucoadhesive or rapid-dissolving buccal films

Note: Specialized applications such as CNS-targeting or mucoadhesive films may require tailored equipment configuration and formulation validation.

Specialized Applications of ODF (Oral Dissolving Films)

Conclusion

ODFs are not just a trend—they're a strategic solution in modern drug delivery. HUANGHAI's ODF manufacturing systems are designed to grow with your needs, offering reliable, scalable, and compliant platforms that bring innovative formulations to market faster and more efficiently.

If you're planning to launch or expand your ODF production, our team of pharmaceutical engineers is ready to assist with technical consultation, line configuration, and scale-up support tailored to your goals.

Explore related equipment: ODF film coating machine | pharmaceutical testing instruments.

Interested in our pharmaceutical equipment? Contact us for a quote.

---

Frequently Asked Questions

Q: What is the difference between an ODF film and a transdermal patch?

A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.

Q: What production output can I expect from a Huanghai ODF machine?

A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.

Q: What drying technology does Huanghai use for ODF production?

A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.

Q: What are the GMP requirements for ODF production equipment?

A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.

Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?

A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.